The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children

BACKGROUND: Drug development for rare diseases is challenging, especially when these orphan drugs (OD) are intended for children. In 2007 the EU Paediatric Drug Regulation was enacted to improve the development of high quality and ethically researched medicines for children through the establishment...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Orphanet J Rare Dis
Main Authors: Kreeftmeijer-Vegter, Annemarie Rosan, de Boer, Anthonius, van der Vlugt-Meijer, Roselinda H, de Vries, Peter J
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2014
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4237943/
https://ncbi.nlm.nih.gov/pubmed/25091201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-014-0120-x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares